HK1206644A1 - Lipid-derived neutral nanoparticles - Google Patents
Lipid-derived neutral nanoparticlesInfo
- Publication number
- HK1206644A1 HK1206644A1 HK15107433.3A HK15107433A HK1206644A1 HK 1206644 A1 HK1206644 A1 HK 1206644A1 HK 15107433 A HK15107433 A HK 15107433A HK 1206644 A1 HK1206644 A1 HK 1206644A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- lipid
- derived neutral
- neutral nanoparticles
- nanoparticles
- derived
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1277—Processes for preparing; Proliposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/44—Oxidoreductases (1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
- C12N2310/141—MicroRNAs, miRNAs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/16—Aptamers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3515—Lipophilic moiety, e.g. cholesterol
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y113/00—Oxidoreductases acting on single donors with incorporation of molecular oxygen (oxygenases) (1.13)
- C12Y113/12—Oxidoreductases acting on single donors with incorporation of molecular oxygen (oxygenases) (1.13) with incorporation of one atom of oxygen (internal monooxygenases or internal mixed function oxidases)(1.13.12)
- C12Y113/12007—Photinus-luciferin 4-monooxygenase (ATP-hydrolysing) (1.13.12.7), i.e. firefly-luciferase
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Dispersion Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261617478P | 2012-03-29 | 2012-03-29 | |
| PCT/US2013/034604 WO2013149141A1 (en) | 2012-03-29 | 2013-03-29 | Lipid-derived neutral nanoparticles |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1206644A1 true HK1206644A1 (en) | 2016-01-15 |
Family
ID=49261290
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK15107433.3A HK1206644A1 (en) | 2012-03-29 | 2015-08-03 | Lipid-derived neutral nanoparticles |
Country Status (9)
| Country | Link |
|---|---|
| US (5) | US9877919B2 (xx) |
| EP (2) | EP3865123A1 (xx) |
| JP (1) | JP6211054B2 (xx) |
| CN (1) | CN104487055A (xx) |
| AU (4) | AU2013237874B2 (xx) |
| CA (1) | CA2868030C (xx) |
| ES (1) | ES2858523T3 (xx) |
| HK (1) | HK1206644A1 (xx) |
| WO (1) | WO2013149141A1 (xx) |
Families Citing this family (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110244026A1 (en) | 2009-12-01 | 2011-10-06 | Braydon Charles Guild | Delivery of mrna for the augmentation of proteins and enzymes in human genetic diseases |
| EP3578205A1 (en) | 2010-08-06 | 2019-12-11 | ModernaTX, Inc. | A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof |
| SG190679A1 (en) | 2010-10-01 | 2013-07-31 | Jason Schrum | Engineered nucleic acids and methods of use thereof |
| AU2012236099A1 (en) | 2011-03-31 | 2013-10-03 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
| BR112013031553A2 (pt) | 2011-06-08 | 2020-11-10 | Shire Human Genetic Therapies, Inc. | composições, mrna que codifica para uma hgla e seu uso, uso de pelo menos uma molécula de mrna e um veículo de transferência e uso de um mrna que codifica para proteína exógena |
| EP4212514A1 (en) | 2011-06-08 | 2023-07-19 | Translate Bio, Inc. | Cleavable lipids |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| SG11201401196WA (en) | 2011-10-03 | 2014-05-29 | Moderna Therapeutics Inc | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
| AU2012352180A1 (en) | 2011-12-16 | 2014-07-31 | Moderna Therapeutics, Inc. | Modified nucleoside, nucleotide, and nucleic acid compositions |
| EP2830595B1 (en) | 2012-03-29 | 2019-10-16 | Translate Bio, Inc. | Ionizable cationic lipids |
| CN104487055A (zh) | 2012-03-29 | 2015-04-01 | 夏尔人类遗传性治疗公司 | 脂质衍生的中性纳米颗粒 |
| US9303079B2 (en) | 2012-04-02 | 2016-04-05 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| US9192651B2 (en) | 2012-04-02 | 2015-11-24 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of secreted proteins |
| US20150267192A1 (en) | 2012-06-08 | 2015-09-24 | Shire Human Genetic Therapies, Inc. | Nuclease resistant polynucleotides and uses thereof |
| US9597380B2 (en) | 2012-11-26 | 2017-03-21 | Modernatx, Inc. | Terminally modified RNA |
| EP2971010B1 (en) | 2013-03-14 | 2020-06-10 | ModernaTX, Inc. | Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions |
| UA117008C2 (uk) | 2013-03-14 | 2018-06-11 | Шир Хьюман Дженетік Терапіс, Інк. | IN VITRO ТРАНСКРИБОВАНА мРНК ТА КОМПОЗИЦІЯ, ЩО ЇЇ МІСТИТЬ, ДЛЯ ЗАСТОСУВАННЯ В ЛІКУВАННІ МУКОВІСЦИДОЗУ В ССАВЦЯ |
| EA201591229A1 (ru) | 2013-03-14 | 2016-01-29 | Шир Хьюман Дженетик Терапис, Инк. | Способы очистки матричной рнк |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| EP3052106A4 (en) | 2013-09-30 | 2017-07-19 | ModernaTX, Inc. | Polynucleotides encoding immune modulating polypeptides |
| MX2016004249A (es) | 2013-10-03 | 2016-11-08 | Moderna Therapeutics Inc | Polinulcleotidos que codifican el receptor de lipoproteina de baja densidad. |
| CA2928186A1 (en) | 2013-10-22 | 2015-04-30 | Shire Human Genetic Therapies, Inc. | Mrna therapy for phenylketonuria |
| CN105658800A (zh) | 2013-10-22 | 2016-06-08 | 夏尔人类遗传性治疗公司 | Mrna的cns递送及其用途 |
| EP3501605B1 (en) | 2013-10-22 | 2023-06-28 | Translate Bio, Inc. | Mrna therapy for argininosuccinate synthetase deficiency |
| RS58337B1 (sr) * | 2014-03-24 | 2019-03-29 | Translate Bio Inc | Irnk terapija za lečenje očnih oboljenja |
| SG10201912038TA (en) | 2014-04-23 | 2020-02-27 | Modernatx Inc | Nucleic acid vaccines |
| KR102470198B1 (ko) | 2014-04-25 | 2022-11-22 | 샤이어 휴먼 지네틱 테라피즈 인크. | 메신저 rna 의 정제 방법 |
| US10117886B2 (en) | 2014-05-30 | 2018-11-06 | Hao Cheng | Hyaluronidase and a low density second PEG layer on the surface of therapeutic-encapsulated nanoparticles to enhance nanoparticle diffusion and circulation |
| RS61607B1 (sr) * | 2015-07-22 | 2021-04-29 | Nitto Denko Corp | Kompozicije i postupci za nanočestične liofilne oblike |
| RS63030B1 (sr) | 2015-09-17 | 2022-04-29 | Modernatx Inc | Jedinjenja i kompozicije za intracelularno isporučivanje terapeutskih sredstava |
| EP3364983A4 (en) | 2015-10-22 | 2019-10-23 | ModernaTX, Inc. | VACCINES AGAINST RESPIRATORY VIRUS |
| CA3007955A1 (en) * | 2015-12-10 | 2017-06-15 | Modernatx, Inc. | Lipid nanoparticles for delivery of therapeutic agents |
| US10799463B2 (en) | 2015-12-22 | 2020-10-13 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of agents |
| MA45053A (fr) | 2016-05-18 | 2019-03-27 | Modernatx Inc | Polynucléotides codant pour un régulateur de conductance transmembranaire de fibrose kystique pour le traitement de la fibrose kystique |
| CN109562153A (zh) * | 2016-08-07 | 2019-04-02 | 诺华股份有限公司 | mRNA介导的免疫方法 |
| WO2018089540A1 (en) | 2016-11-08 | 2018-05-17 | Modernatx, Inc. | Stabilized formulations of lipid nanoparticles |
| BR112019012999A2 (pt) * | 2016-12-21 | 2019-12-10 | Nanobiotix | nanopartículas revestidas para uso para modular a polarização elétrica de neurônios |
| WO2018157154A2 (en) | 2017-02-27 | 2018-08-30 | Translate Bio, Inc. | Novel codon-optimized cftr mrna |
| AU2018224843A1 (en) | 2017-02-27 | 2019-09-19 | Translate Bio, Inc. | Methods for purification of messenger RNA |
| EP3585892B8 (en) | 2017-02-27 | 2022-07-13 | Translate Bio, Inc. | Methods for purification of messenger rna |
| ES2940259T3 (es) | 2017-03-15 | 2023-05-04 | Modernatx Inc | Compuesto y composiciones para la administración intracelular de agentes terapéuticos |
| CA3056133A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Crystal forms of amino lipids |
| CA3055653A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Lipid nanoparticle formulation |
| MA48047A (fr) | 2017-04-05 | 2020-02-12 | Modernatx Inc | Réduction ou élimination de réponses immunitaires à des protéines thérapeutiques administrées par voie non intraveineuse, par exemple par voie sous-cutanée |
| WO2018213476A1 (en) | 2017-05-16 | 2018-11-22 | Translate Bio, Inc. | Treatment of cystic fibrosis by delivery of codon-optimized mrna encoding cftr |
| EP3638215A4 (en) | 2017-06-15 | 2021-03-24 | Modernatx, Inc. | RNA FORMULATIONS |
| JP7275111B2 (ja) | 2017-08-31 | 2023-05-17 | モデルナティエックス インコーポレイテッド | 脂質ナノ粒子の生成方法 |
| MA50803A (fr) | 2017-11-22 | 2020-09-30 | Modernatx Inc | Polynucléotides codant pour l'ornithine transcarbamylase pour le traitement de troubles du cycle de l'urée |
| CA3089264A1 (en) | 2018-02-01 | 2019-08-08 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Methods and devices for reducing vacular smooth muscle cell proliferation |
| WO2019165267A1 (en) | 2018-02-22 | 2019-08-29 | The Regents Of The University Of California | Methods for treating brain injury |
| CN115350154A (zh) * | 2018-03-30 | 2022-11-18 | 美商Tlc生物医药公司 | 用以制备麻醉剂组成物的脂质饼块及其用途 |
| US20210220449A1 (en) * | 2018-05-15 | 2021-07-22 | Translate Bio, Inc. | Subcutaneous Delivery of Messenger RNA |
| CA3108544A1 (en) | 2018-08-24 | 2020-02-27 | Translate Bio, Inc. | Methods for purification of messenger rna |
| AU2019333042A1 (en) * | 2018-08-29 | 2021-03-04 | Translate Bio, Inc. | Improved process of preparing mRNA-loaded lipid nanoparticles |
| US20210388338A1 (en) | 2018-11-08 | 2021-12-16 | Translate Bio, Inc. | Methods and Compositions for Messenger RNA Purification |
| AU2020340290A1 (en) * | 2019-08-24 | 2022-04-07 | Flagship Pioneering Innovations Vi, Llc | Modification of plant messenger packs with charged lipids |
| EP4025196A4 (en) * | 2019-09-06 | 2023-07-12 | Generation Bio Co. | LIPID-NANOPARTICLE COMPOSITIONS WITH CLOSED-END DNA AND CLEAVABLE LIPIDS AND METHODS OF USE |
| EP4031524A1 (en) | 2019-09-19 | 2022-07-27 | ModernaTX, Inc. | Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents |
| KR20230052895A (ko) * | 2020-07-17 | 2023-04-20 | 제너레이션 바이오 컴퍼니 | 폴리뉴클레오타이드를 감소된 크기의 지질 나노입자로 캡슐화하는 방법 및 신규한 지질 나노입자 제형 |
| US11771652B2 (en) | 2020-11-06 | 2023-10-03 | Sanofi | Lipid nanoparticles for delivering mRNA vaccines |
| US11524023B2 (en) | 2021-02-19 | 2022-12-13 | Modernatx, Inc. | Lipid nanoparticle compositions and methods of formulating the same |
| FR3121360B1 (fr) * | 2021-03-30 | 2024-05-31 | Commissariat Energie Atomique | Formulation pour la délivrance d’ARN messager |
| BR112023021504A2 (pt) * | 2021-04-20 | 2023-12-19 | Generation Bio Co | Lipídios catiônicos e composições dos mesmos |
| KR20240049810A (ko) | 2021-09-03 | 2024-04-17 | 큐어백 에스이 | 핵산 전달용 신규 지질 나노입자 |
| WO2023073228A1 (en) | 2021-10-29 | 2023-05-04 | CureVac SE | Improved circular rna for expressing therapeutic proteins |
| AU2022398450A1 (en) * | 2021-11-23 | 2024-06-06 | Sail Biomedicines, Inc. | A bacteria-derived lipid composition and use thereof |
| CA3242118A1 (en) | 2021-12-22 | 2023-06-29 | Alfica Sehgal | Modulation of gene transcription using antisense oligonucleotides targeting regulatory rnas |
| WO2023144330A1 (en) | 2022-01-28 | 2023-08-03 | CureVac SE | Nucleic acid encoded transcription factor inhibitors |
| CN114907243B (zh) * | 2022-02-28 | 2023-10-27 | 东南大学 | 一种可离子化脂质、其组合物及应用 |
| WO2023227608A1 (en) | 2022-05-25 | 2023-11-30 | Glaxosmithkline Biologicals Sa | Nucleic acid based vaccine encoding an escherichia coli fimh antigenic polypeptide |
| WO2023240277A2 (en) | 2022-06-10 | 2023-12-14 | Camp4 Therapeutics Corporation | Methods of modulating progranulin expression using antisense oligonucleotides targeting regulatory rnas |
| DE202023106198U1 (de) | 2022-10-28 | 2024-03-21 | CureVac SE | Impfstoff auf Nukleinsäurebasis |
| WO2024119145A1 (en) | 2022-12-01 | 2024-06-06 | Camp4 Therapeutics Corporation | Modulation of syngap1 gene transcription using antisense oligonucleotides targeting regulatory rnas |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4897355A (en) | 1985-01-07 | 1990-01-30 | Syntex (U.S.A.) Inc. | N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| US5223263A (en) | 1988-07-07 | 1993-06-29 | Vical, Inc. | Liponucleotide-containing liposomes |
| US4737323A (en) | 1986-02-13 | 1988-04-12 | Liposome Technology, Inc. | Liposome extrusion method |
| DE3728917A1 (de) | 1987-08-29 | 1989-03-09 | Roth Hermann J | Neue lipide mit unsymmetrisch substituierter disulfidbruecke |
| US4946683A (en) | 1987-11-18 | 1990-08-07 | Vestar, Inc. | Multiple step entrapment/loading procedure for preparing lipophilic drug-containing liposomes |
| FR2645866B1 (fr) | 1989-04-17 | 1991-07-05 | Centre Nat Rech Scient | Nouvelles lipopolyamines, leur preparation et leur emploi |
| US5194654A (en) | 1989-11-22 | 1993-03-16 | Vical, Inc. | Lipid derivatives of phosphonoacids for liposomal incorporation and method of use |
| US5334761A (en) | 1992-08-28 | 1994-08-02 | Life Technologies, Inc. | Cationic lipids |
| US5885613A (en) | 1994-09-30 | 1999-03-23 | The University Of British Columbia | Bilayer stabilizing components and their use in forming programmable fusogenic liposomes |
| US5965434A (en) * | 1994-12-29 | 1999-10-12 | Wolff; Jon A. | Amphipathic PH sensitive compounds and delivery systems for delivering biologically active compounds |
| US5744335A (en) | 1995-09-19 | 1998-04-28 | Mirus Corporation | Process of transfecting a cell with a polynucleotide mixed with an amphipathic compound and a DNA-binding protein |
| CA2289702C (en) * | 1997-05-14 | 2008-02-19 | Inex Pharmaceuticals Corp. | High efficiency encapsulation of charged therapeutic agents in lipid vesicles |
| WO1998058630A1 (en) * | 1997-06-23 | 1998-12-30 | Sequus Pharmaceuticals, Inc. | Liposome-entrapped polynucleotide composition and method |
| EP2292771A3 (en) * | 1997-09-19 | 2011-07-27 | Life Technologies Corporation | Sense mRNA therapy |
| US6169078B1 (en) * | 1998-05-12 | 2001-01-02 | University Of Florida | Materials and methods for the intracellular delivery of substances |
| US6379698B1 (en) * | 1999-04-06 | 2002-04-30 | Isis Pharmaceuticals, Inc. | Fusogenic lipids and vesicles |
| KR100669053B1 (ko) | 1999-04-23 | 2007-01-15 | 알자 코포레이션 | 리포좀에 사용하기 위한 절단가능 결합을 갖는 콘쥬게이트 |
| WO2001005375A1 (en) | 1999-07-16 | 2001-01-25 | Purdue Research Foundation | Vinyl ether lipids with cleavable hydrophilic headgroups |
| MXPA05010499A (es) * | 2003-03-31 | 2006-05-25 | Johnson & Johnson | Particulas lipidicas que tienen un revestimiento lipidico asimetrico y metodo de preparacion de las mismas. |
| JP4842821B2 (ja) | 2003-09-15 | 2011-12-21 | プロチバ バイオセラピューティクス インコーポレイティッド | ポリエチレングリコール修飾脂質化合物およびその使用 |
| US7799565B2 (en) | 2004-06-07 | 2010-09-21 | Protiva Biotherapeutics, Inc. | Lipid encapsulated interfering RNA |
| WO2007086883A2 (en) | 2005-02-14 | 2007-08-02 | Sirna Therapeutics, Inc. | Cationic lipids and formulated molecular compositions containing them |
| WO2007031091A2 (en) | 2005-09-15 | 2007-03-22 | Santaris Pharma A/S | Rna antagonist compounds for the modulation of p21 ras expression |
| EP2395012B8 (en) | 2005-11-02 | 2018-06-06 | Arbutus Biopharma Corporation | Modified siRNA molecules and uses thereof |
| WO2009030254A1 (en) | 2007-09-04 | 2009-03-12 | Curevac Gmbh | Complexes of rna and cationic peptides for transfection and for immunostimulation |
| CN102245590B (zh) | 2008-10-09 | 2014-03-19 | 泰米拉制药公司 | 改善的氨基脂质和递送核酸的方法 |
| MX359674B (es) | 2008-11-10 | 2018-10-05 | Alnylam Pharmaceuticals Inc | Lipidos y composiciones novedosas para el suministro de terapeuticos. |
| US9018187B2 (en) | 2009-07-01 | 2015-04-28 | Protiva Biotherapeutics, Inc. | Cationic lipids and methods for the delivery of therapeutic agents |
| DE102009043342A1 (de) | 2009-09-29 | 2011-03-31 | Bayer Technology Services Gmbh | Stoffe für selbstorganisierte Träger zur kontrollierten Freisetzung eines Wirkstoffs |
| US20110244026A1 (en) | 2009-12-01 | 2011-10-06 | Braydon Charles Guild | Delivery of mrna for the augmentation of proteins and enzymes in human genetic diseases |
| AU2012236099A1 (en) | 2011-03-31 | 2013-10-03 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
| BR112013031553A2 (pt) | 2011-06-08 | 2020-11-10 | Shire Human Genetic Therapies, Inc. | composições, mrna que codifica para uma hgla e seu uso, uso de pelo menos uma molécula de mrna e um veículo de transferência e uso de um mrna que codifica para proteína exógena |
| EP4212514A1 (en) | 2011-06-08 | 2023-07-19 | Translate Bio, Inc. | Cleavable lipids |
| US8999950B2 (en) | 2011-10-05 | 2015-04-07 | Protiva Biotherapeutics Inc. | Compositions and methods for silencing aldehyde dehydrogenase |
| EP2791159A4 (en) | 2011-12-14 | 2015-10-14 | Moderna Therapeutics Inc | MODIFIED NUCLEIC ACIDS, AND SHORT-TERM CARE USES THEREOF |
| CN104968354A (zh) | 2011-12-21 | 2015-10-07 | 现代治疗公司 | 增加器官或器官外植体的活力或寿命的方法 |
| RU2718053C2 (ru) | 2012-02-24 | 2020-03-30 | Протива Байотерапьютикс Инк. | Триалкиловые катионные липиды и способы их использования |
| CN104487055A (zh) | 2012-03-29 | 2015-04-01 | 夏尔人类遗传性治疗公司 | 脂质衍生的中性纳米颗粒 |
| US9192651B2 (en) | 2012-04-02 | 2015-11-24 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of secreted proteins |
| US9303079B2 (en) | 2012-04-02 | 2016-04-05 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| US20150050354A1 (en) | 2012-04-02 | 2015-02-19 | Moderna Therapeutics, Inc. | Modified polynucleotides for the treatment of otic diseases and conditions |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| LT3019619T (lt) | 2013-07-11 | 2021-12-10 | Modernatx, Inc. | Sintetinius polinukleotidus apimančios kompozicijos, koduojančios susijusius su crispr baltymus ir sintetines sgrnas, ir jų naudojimo būdai |
| CN105555757A (zh) | 2013-07-23 | 2016-05-04 | 普洛体维生物治疗公司 | 用于递送信使rna的组合物和方法 |
-
2013
- 2013-03-29 CN CN201380026368.9A patent/CN104487055A/zh active Pending
- 2013-03-29 WO PCT/US2013/034604 patent/WO2013149141A1/en active Application Filing
- 2013-03-29 EP EP20214617.1A patent/EP3865123A1/en active Pending
- 2013-03-29 EP EP13769005.3A patent/EP2830596B1/en active Active
- 2013-03-29 ES ES13769005T patent/ES2858523T3/es active Active
- 2013-03-29 US US14/389,165 patent/US9877919B2/en active Active
- 2013-03-29 AU AU2013237874A patent/AU2013237874B2/en active Active
- 2013-03-29 CA CA2868030A patent/CA2868030C/en active Active
- 2013-03-29 JP JP2015503637A patent/JP6211054B2/ja active Active
-
2015
- 2015-08-03 HK HK15107433.3A patent/HK1206644A1/xx unknown
-
2018
- 2018-01-23 US US15/878,131 patent/US10137086B2/en active Active
- 2018-01-23 US US15/878,137 patent/US10137087B2/en active Active
- 2018-04-13 AU AU2018202585A patent/AU2018202585B2/en active Active
- 2018-11-06 US US16/182,090 patent/US10786455B2/en active Active
-
2020
- 2020-07-06 AU AU2020204494A patent/AU2020204494B2/en active Active
- 2020-08-26 US US17/003,105 patent/US11497716B2/en active Active
-
2022
- 2022-07-08 AU AU2022204907A patent/AU2022204907A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US11497716B2 (en) | 2022-11-15 |
| ES2858523T3 (es) | 2021-09-30 |
| EP3865123A1 (en) | 2021-08-18 |
| AU2018202585A1 (en) | 2018-05-10 |
| JP6211054B2 (ja) | 2017-10-11 |
| US10137086B2 (en) | 2018-11-27 |
| EP2830596B1 (en) | 2020-12-30 |
| EP2830596A1 (en) | 2015-02-04 |
| AU2013237874A1 (en) | 2014-10-02 |
| US9877919B2 (en) | 2018-01-30 |
| US20210038519A1 (en) | 2021-02-11 |
| JP2015518472A (ja) | 2015-07-02 |
| EP2830596A4 (en) | 2016-04-13 |
| US20180169015A1 (en) | 2018-06-21 |
| AU2020204494B2 (en) | 2022-04-14 |
| AU2013237874B2 (en) | 2018-01-18 |
| WO2013149141A1 (en) | 2013-10-03 |
| AU2020204494A1 (en) | 2020-07-23 |
| AU2018202585B2 (en) | 2020-04-09 |
| US10137087B2 (en) | 2018-11-27 |
| US20150086613A1 (en) | 2015-03-26 |
| CN104487055A (zh) | 2015-04-01 |
| CA2868030A1 (en) | 2013-10-03 |
| US20190192435A1 (en) | 2019-06-27 |
| US10786455B2 (en) | 2020-09-29 |
| US20180169016A1 (en) | 2018-06-21 |
| AU2022204907A1 (en) | 2022-08-11 |
| CA2868030C (en) | 2021-05-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1206644A1 (en) | Lipid-derived neutral nanoparticles | |
| IL254716B (en) | Zinc-lysine conjugate | |
| EP2833926A4 (en) | NEUROPHILIC NANOPARTICLES | |
| DK3327112T3 (en) | Agse-deficient stamme | |
| EP2754580A4 (en) | DUMP TRUCK | |
| DK2830816T3 (en) | Hidtil ukendt coatingkoncept | |
| HK1211862A1 (en) | Nanoparticle formulation | |
| EP2935220A4 (en) | PERI-carbinol | |
| EP2920142A4 (en) | MÉTHANOFULLERRÈNES | |
| GB201216930D0 (en) | Nanoparticles | |
| EP2812698A4 (en) | TIME RESOLVED FREIGHT AND DOUBLE ACCEPTOR | |
| HK1198963A1 (en) | Pruefanlage | |
| EP2920157A4 (en) | DI MACRO CYCLEN | |
| EP2873363A4 (en) | DIOPSIMETER | |
| GB201209517D0 (en) | Nanoparticles | |
| EP2891144A4 (en) | HANDLING PARAMETERS | |
| GB201209739D0 (en) | Aerobars | |
| GB2510699B (en) | Push-scooter | |
| EP2834250A4 (de) | Lithiumsilikate | |
| GB201214251D0 (en) | Rule | |
| IL224862A0 (en) | visual aids | |
| GB201221315D0 (en) | Moderate IT | |
| GB201223529D0 (en) | CUshbee | |
| GB201222889D0 (en) | Corriclip | |
| IL223332A0 (en) | device |